Related Experiment Videos
[Morphological and metabolic abnormalities related to antiretroviral therapy]
Abstract:
The long term use of antiretroviral therapy is associated with metabolic and morphological abnormalities named lipodystrophy. The understanding of its epidemiology is in progress. NRTIs and Pls are involved in the origin of these abnormalities. So, NRTIs inhibit mitochondrial gamma polymerase and induce body fat distribution disorders. PIs interfere with lipid metabolism, leading to hyperlipidaemia and insulin resistance symptomatology. The diagnosis is made by clinical (far wasting or accumulation, or mixed syndrome) and biological signs (hyperlipidaemia, hyperglycaemia, hyperlactacidaemia). Radiological exams can quantify morphological abnormalities. The management consists in drug substitution, diet and exercise, and corrective drugs. Plastic surgery can be useful.
Insights
Long-term antiretroviral therapy can cause lipodystrophy, a condition with metabolic and fat distribution issues. Nucleoside reverse transcriptase inhibitors and protease inhibitors are implicated in its development.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
- Infectious Diseases
Context:
- Antiretroviral therapy (ART) is crucial for managing HIV/AIDS.
- Long-term ART use is linked to adverse metabolic and morphological changes.
- Lipodystrophy is a significant concern in patients on prolonged ART.
Purpose:
- To elucidate the mechanisms behind ART-induced lipodystrophy.
- To outline diagnostic criteria and management strategies for lipodystrophy.
- To improve understanding of the epidemiology of this condition.
Summary:
- Nucleoside reverse transcriptase inhibitors (NRTIs) disrupt mitochondrial function, leading to fat redistribution disorders.
- Protease inhibitors (PIs) negatively impact lipid metabolism, causing hyperlipidemia and insulin resistance.
- Diagnosis involves clinical signs (fat wasting/accumulation) and biological markers (hyperlipidemia, hyperglycemia, hyperlactatemia).
Impact:
- Highlights the need for monitoring metabolic and morphological changes in patients on ART.
- Informs clinical practice regarding diagnosis and management of lipodystrophy.
- Suggests therapeutic avenues including drug substitution, lifestyle changes, and corrective medications.